Heart Failure Drug Trial Results Have Disappointed
New research shows high-dose tovinontrine failed to lower heart failure biomarkers as expected in clinical trials.
Updated on Oct. 11, 2026 in Heart Disease
Live Poll
Do clinical trial failures generally make you less confident in the development of new heart medicines?
Tovinontrine failed to meet effectiveness goals for reducing NT-proBNP levels in two phase II heart failure trials. The studies involved patients with HFrEF and HFpEF who were monitored over a 12-week period.
Why it matters
Researchers believe an inverse dose response may exist, suggesting that high doses of the medication could be counterproductive for heart failure management. This finding shifts the focus toward investigating lower-dose strategies to potentially improve therapeutic outcomes.
In two phase II trials involving 529 HFrEF and 277 HFpEF participants, tovinontrine failed to meet expectations for reducing NT-proBNP levels at week 12. While plasma cGMP increased, higher doses showed an inverse response compared to lower doses.
The details
Tovinontrine aims to affect heart failure by modulating myocardial cGMP levels. Investigators now suspect there is a biological ceiling for how much cGMP can be elevated before compensatory mechanisms trigger an ineffective or negative response. The trials showed that while the drug successfully increased cGMP, the high-dose groups did not achieve the desired reduction in NT-proBNP, a common biomarker used to track heart failure severity.
Timeline
Week 4: Plasma cGMP increased from baseline measurements.
Week 12: Primary outcome measurement for NT-proBNP reduction.
2027: Scheduled start of the CYCLE-3 trial.
Health Landscape
These findings update the progress of the CYCLE heart failure trial series currently evaluating novel therapeutic pathways. The data indicate a pivot from previously hypothesized high-dose models toward lower-dose interventions in the ongoing effort to manage cardiac biomarkers.
These results emphasize that higher doses of a medication are not always more effective and can sometimes cause unexpected physiological responses. Any concerns regarding your current heart failure treatment plan are worth discussing with your doctor to ensure your regimen remains optimized for your health.
The takeaway
The study highlights the complexity of drug dosing where more is not always better for managing chronic heart failure biomarkers. Patients should continue to monitor their heart health regularly and track any changes in symptoms for discussion with their primary care physician or cardiologist.
What happens next
The CYCLE-3 phase IIb study is scheduled to begin in 2027 to evaluate the efficacy of lower tovinontrine doses in patients with HFrEF.
Further reading
For more information on the current landscape of cardiac research, visit the Heart Disease section.
Source note: This article includes information reported by MedPage Today.
Live Poll
Do clinical trial failures generally make you less confident in the development of new heart medicines?
